The European Medicines Agency, EMA, will take the decision to approve the Russian Sputnik V vaccine in the first quarter of 2022, as according to the company, the data so far are insufficient. 

"The EMA decision by the end of the year is now completely impossible," sources announce. 

If the required data arrives by the end of November, "then regulators can make a decision in the first quarter of next year," added a source who wished to remain anonymous. 
The EMA launched an official test of the Russian vaccine in March. It was previously expected to be approved in May or June. 

The results of the third phase of clinical trials, published in February in the medical journal 'The Lancet', showed that the vaccine was almost 92 percent effective. Russia later announced that it has an 83 percent effectiveness against the delta variant of the virus, a mutation that dominates the world today.